Aurora Cannabis has told its shareholders to reject Curaleaf’s improved hostile takeover offer, setting up a roughly seven-week standoff in one of the cannabis industry’s largest unsolicited deals. In an Oct. 14, 2026 announcement, Aurora said its board, acting on the unanimous recommendation of a special committee of independent directors, found the revised bid inadequate. Curaleaf’s offer is open until Dec. 4, 2026.
Here is what is on the table, what each side says, and what could happen next. This article is news analysis, not investment advice.
What Curaleaf is offering
Curaleaf Holdings launched its formal take-over bid for all of Aurora’s common shares on Aug. 18, 2026. The original terms were 0.3463 of a Curaleaf subordinate voting share plus US$0.75 in cash for each Aurora share, which Curaleaf valued at about US$4.00 per share. It described that as a 45% premium to Aurora’s “unaffected” share price, measured before the offer became public on Aug. 10.
On Oct. 6, Curaleaf filed a Notice of Variation, Change and Extension that raised the offer. According to the filing, each Aurora share would now receive:
- US$1.00 in cash, up from US$0.75.
- 0.4013 of a Curaleaf subordinate voting share, up from 0.3463.
- A total value cap of US$6.00 per share, up from US$5.00. If Curaleaf’s share price rises above a set threshold, the share ratio falls so the value stays at the cap.
Aurora’s own statement put the implied value of the revised offer at US$5.00 per share, based on Curaleaf’s Oct. 2 closing price. The offer deadline moved from Dec. 1 to 11:59 p.m. Mountain Time on Dec. 4, 2026. Because most of the consideration is stock, the real value to Aurora shareholders will move with Curaleaf’s share price.
Why Aurora’s board says no
Aurora’s board gave several reasons for recommending rejection. According to the company’s release:
- Its financial advisor delivered an updated fairness opinion concluding the revised consideration is inadequate from a financial point of view.
- Aurora says it is debt-free with a strong cash position, and that a significant part of the cash in the offer would effectively be funded by Aurora’s own balance sheet.
- Most of the increase is in Curaleaf shares, which Aurora argues are valued too high. Shareholders who tender would bear the risk of any drop in Curaleaf’s stock.
- Aurora calls the bid opportunistic and says Curaleaf has not adequately supported its claimed synergies, with most of the benefit going to Curaleaf’s own shareholders.
- The board says superior alternatives may emerge from a strategic review now under way.
Aurora Executive Chairman and CEO Miguel Martin said shareholders “gain nothing by tendering now.” Shareholders do not need to take any action to reject the offer.
Curaleaf’s argument
Curaleaf says the offer gives Aurora shareholders a significant premium, exposure to the U.S. market, and a larger combined company. Its filing describes a combined business operating in 17 countries, with more than US$1.5 billion in trailing 12-month revenue and at least US$40 million in annual cost synergies. These are Curaleaf’s own projections and have not been independently verified.
Curaleaf also says Aurora’s leadership has refused to engage in substantive discussions, and that it stands ready to talk at any time. In its August announcement, Curaleaf pointed to pressure on Aurora’s core medical cannabis business from lower Canadian reimbursement rates and the end of German reimbursement, and to repeated impairment charges in recent years. Aurora disputes the conclusion that the offer reflects its value.
Regulatory and strategic moves
The contest is also playing out before securities regulators. According to Curaleaf’s filing, it asked the Alberta Securities Commission on Sept. 14 to halt Aurora’s at-the-market share issuances while the bid is open. Aurora has separately challenged the bid’s compliance with securities rules. Neither application had been resolved in the sources reviewed for this article.
Meanwhile, Aurora’s special committee is exploring alternatives, including a deal with a third party or remaining independent. The company says it has signed confidentiality and standstill agreements with multiple parties and held numerous discussions. It says no outcome is guaranteed and promised a further recommendation, plus a Notice of Change with fuller reasoning, after the review.
Why it matters
The bid is a test of how consolidation might unfold in an industry that has struggled with weak valuations and tight capital. A Curaleaf-Aurora combination would join a major U.S. multi-state operator with a Canadian licensed producer that has a significant international medical cannabis business. U.S. cannabis operators remain restricted by federal law, which shapes how and where they can raise money. For background on those constraints, see our guides on cannabis investing risks and considerations and whether to invest in cannabis stocks.
Federal policy is also part of the backdrop. A move to reclassify marijuana would affect the tax and banking position of U.S. operators, but the process is currently stalled. Our coverage explains why the DEA rescheduling hearing is on pause and the latest order in the hearing.
What happens next
- Dec. 4, 2026: Curaleaf’s current expiry date. It can be extended or changed again.
- Aurora’s strategic review: The board has promised a further recommendation once it finishes.
- Alberta Securities Commission: Rulings on the competing applications could affect the timeline.
- Closing conditions: Under the original terms, the bid requires a majority of shares tendered excluding Curaleaf and other non-independent holders, at least 66â…”% of shares on a fully diluted basis, and regulatory approvals.
Shareholders weighing the decision should read the offer documents and the Directors’ Circular directly, and consider talking with a licensed financial adviser.
Sources
- Curaleaf Notice of Variation, Change and Extension, Oct. 6, 2026 (SEC filing)
- Aurora Cannabis board recommendation to reject the revised bid, Oct. 14, 2026 (PR Newswire)
- Aurora Cannabis response to the revised bid, Oct. 6, 2026 (PR Newswire)
- Curaleaf launches take-over bid for Aurora Cannabis, Aug. 18, 2026 (company press release)
- Aurora board tells shareholders to reject Curaleaf’s revised hostile bid (MJBizDaily)
